Lupin’s subsidiary receives green signal for anti-AIDS generic drug

16 May 2012 Evaluate

Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Lamivudine and Zidovudine Tablets, 150 mg/300 mg from the United States Food and Drugs Administration (FDA). Lupin has already commenced shipping the product.

Lupin’s Lamivudine and Zidovudine Tablets are the AB rated generic equivalent of Viiv Healthcare’s Combivir  Tablets, 150/300 mg. Combivir Tablets, had annual US sales of approximately $27.5 crore for the twelve months ending December 2011 (IMS Health Sales Data).

Lamivudine Zidovudine is a combination of two nucleoside analogue reverse transcriplase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Lupin Share Price

2079.50 -33.45 (-1.58%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×